Status:
UNKNOWN
Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary Syndrome
Lead Sponsor:
University of Virginia
Conditions:
Polycystic Ovary Syndrome
Eligibility:
FEMALE
18-35 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine whether a testosterone receptor blocker (flutamide) will normalize sleep-wake luteinizing hormone pulse frequency relationships in women with polycystic ovary...
Detailed Description
During the follicular phase of the normal menstrual cycle, luteinizing hormone (LH) pulse frequency decreases during sleep. These decreases may be important to support follicle stimulating hormone (FS...
Eligibility Criteria
Inclusion
- Inclusion criteria for all participants:
- Subjects will be 18-35 years old; we use a cutoff age of 35 y because early menopause at this age is very rare.
- No significant health problems (other than PCOS and obesity).
- Subjects will be willing to strictly avoid pregnancy (using non-hormonal methods) during the time of study and must be willing and able to provide informed consent.
- Inclusion criteria for normal controls:
- Controls will be healthy women with regular menstrual cycles and no evidence of hyperandrogenism.
- Inclusion criteria for PCOS:
- PCOS will be defined according to NIH consensus criteria.
- As such, subjects with PCOS will have hyperandrogenism, whether it is clinical (e.g., hirsutism) or biochemical (i.e., elevated plasma T).
- Subjects with PCOS will also have oligo- or amenorrhea (i.e., \< 7 periods per year) and no evidence for other endocrinopathies (e.g., hyperprolactinemia, Cushing's syndrome, etc.).
Exclusion
- Being a study of GnRH pulse regulation in women with and without PCOS, men are excluded.
- Obesity associated with a diagnosed (genetic) syndrome, obesity related to medications (e.g., glucocorticoids), etc.
- Pregnancy or lactation.
- Virilization.
- A total testosterone \> 150 ng/dl in women with PCOS (which suggests the possibility of a virilizing neoplasm) (confirmed on repeat).
- Elevated DHEAS (mild elevations may be seen in PCOS, and elevations \< 1.5 times the upper limit of normal will be accepted in PCOS)(confirmed on repeat).
- Follicular 17-hydroxyprogesterone \> 300 ng/dl, which suggests the possibility of congenital adrenal hyperplasia (if elevated during the luteal phase and there is a concern about the possibility of congenital adrenal hyperplasia, the 17-hydroxyprogesterone may be collected during the follicular phase, or \>60 if oligomenorrheic).
- \*NOTE: If a 17-hydroxyprogesterone \> 300 ng/dl is confirmed on such repeat testing, an ACTH stimulated 17-hydroxyprogesterone \< 1000 ng/dl will be required for study participation.
- A previous diagnosis of diabetes, a fasting glucose ≥ 126 mg/dl, or a hemoglobin A1c \> 6.5%
- Abnormal TSH (subjects with adequately treated hypothyroidism, reflected by normal TSH values, will not be excluded; or, for a new diagnosis of hypothyroidism, further study will at the least be delayed pending appropriate treatment) (confirmed on repeat).
- Abnormal prolactin (mild elevations may be seen in PCOS, and elevations \< 1.5 times the upper limit of normal will be accepted in this group) (confirmed on repeat).
- Evidence of Cushing's syndrome by history or physical exam.
- Hematocrit \< 36% or hemoglobin \< 12 g/dl (that is not reversed by iron treatment).
- Significant history of cardiac or pulmonary dysfunction (e.g., known or suspected congestive heart failure; asthma requiring intermittent systemic corticosteroids; etc.)
- Liver test abnormalities (confirmed on repeat), with the exception that mild bilirubin elevations will be accepted in the setting of known Gilbert's syndrome.
- Abnormal sodium or potassium (confirmed on repeat); bicarbonate concentration \<20 or \>30 (confirmed on repeat); or elevated creatinine concentration (confirmed on repeat).
- Due to the amount of blood being drawn in the study, subjects with body weight \< 110 lbs will be excluded from the study.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2024
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00930228
Start Date
January 1 2009
End Date
August 1 2024
Last Update
November 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Virginia
Charlottesville, Virginia, United States, 22908